HaemaLogiX Overview
- Founded
-
2014

- Status
-
Private
- Employees
-
5

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$10M
- Investors
-
2
HaemaLogiX General Information
Description
Developer of a novel immuno-oncology and immune therapies designed for the treatment of hematologic malignancies and auto-immune diseases. The company is focused on the development and commercialization of monoclonal antibodies for the potential treatment of multiple myeloma and potentially other blood cancers, enabling clients to get targets that are highly specific to the cancer cells identified in blood cancers.
Contact Information
Website
www.haemalogix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 80 William Street
- Suite 204
- Woolloomooloo, New South Wales 2011
- Australia
HaemaLogiX Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Later Stage VC | 08-Sep-2021 | $10M | 0000 | Completed | Generating Revenue | |
1. Accelerator/Incubator | Completed | Startup |
HaemaLogiX Patents
HaemaLogiX Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020900948-A0 | Composition and method | Inactive | 27-Mar-2020 | ||
EP-3890780-A1 | Method of treatment | Pending | 03-Dec-2018 | 0000000000 | |
EP-3890780-A4 | Method of treatment | Pending | 03-Dec-2018 | 0000000000 | |
US-20220031840-A1 | Method of treatment | Pending | 03-Dec-2018 | 0000000000 | |
AU-2019392579-A1 | Method of treatment | Pending | 03-Dec-2018 | A61K39/395 |
HaemaLogiX Executive Team (5)
HaemaLogiX Board Members (4)
Name | Representing | Role | Since |
---|---|---|---|
Alan Liddle | HaemaLogiX | Co-Founder & Board Member | 000 0000 |
Bryce Carmine | HaemaLogiX | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
Geoff Nichol | Self | Board Member | 000 0000 |
John Cullity | Self | Board Member | 000 0000 |
HaemaLogiX Signals
HaemaLogiX Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Platinum Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 | |
Cicada Innovations | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |